

Mark D Danese

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5778792/publications.pdf>

Version: 2024-02-01

69
papers

3,679
citations

257101

24
h-index

128067

60
g-index

70
all docs

70
docs citations

70
times ranked

4173
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-world outcomes with second-line therapy in advanced esophageal squamous cell carcinoma using SEER-Medicare data. <i>Future Oncology</i> , 2022, 18, 927-936.	1.1	2
2	Association Between Granulocyte Colony-Stimulating Factor (G-CSF) Use and Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Among Elderly Patients with Breast, Lung, or Prostate Cancer. <i>Advances in Therapy</i> , 2022, 39, 2778-2795.	1.3	3
3	Longitudinal evaluation of treatment patterns, risk factors and outcomes in patients with cardiovascular disease treated with lipid-lowering therapy in the UK. <i>BMJ Open</i> , 2022, 12, e055015.	0.8	0
4	The rate, cost and outcomes of parathyroidectomy in the united states dialysis population from 2016-2018. <i>BMC Nephrology</i> , 2022, 23, .	0.8	6
5	Fibroblast growth factor 23 as a risk factor for cardiovascular events and mortality in patients in the EVOLVE trial. <i>Hemodialysis International</i> , 2021, 25, 78-85.	0.4	3
6	A comparison of mixture cure fraction models to traditional parametric survival models in estimation of the cost-effectiveness of nivolumab for relapsed small cell lung cancer. <i>Journal of Medical Economics</i> , 2021, 24, 79-86.	1.0	6
7	Treatment patterns and outcomes in older patients with advanced malignant pleural mesothelioma: Analyses of Surveillance, Epidemiology, and End Results-Medicare data. <i>Cancer Reports</i> , 2021, , e1568.	0.6	2
8	Real World Use and Effects of Calcimimetics in Treating Mineral and Bone Disorder in Hemodialysis Patients. <i>American Journal of Nephrology</i> , 2020, 51, 815-822.	1.4	3
9	The Generalized Data Model for clinical research. <i>BMC Medical Informatics and Decision Making</i> , 2019, 19, 117.	1.5	13
10	Estimated Life Expectancy and Income of Patients With Sickle Cell Disease Compared With Those Without Sickle Cell Disease. <i>JAMA Network Open</i> , 2019, 2, e1915374.	2.8	163
11	Treatment patterns, survival, and hospitalization in adult patients with acute lymphoblastic leukemia: an observational cohort study using SEER Medicare data. <i>Leukemia and Lymphoma</i> , 2019, 60, 2015-2024.	0.6	5
12	The prevalence, low-density lipoprotein cholesterol levels, and treatment of patients at very high risk of cardiovascular events in the United Kingdom: a cross-sectional study. <i>Current Medical Research and Opinion</i> , 2018, 34, 1441-1447.	0.9	8
13	Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe. <i>JAMA Network Open</i> , 2018, 1, e185554.	2.8	67
14	Societal Costs of Sickle Cell Disease in the United States. <i>Blood</i> , 2018, 132, 4706-4706.	0.6	2
15	Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context. <i>Journal of Medical Economics</i> , 2017, 20, 555-564.	1.0	49
16	Methods for estimating costs in patients with hyperlipidemia experiencing their first cardiovascular event in the United Kingdom. <i>Journal of Medical Economics</i> , 2017, 20, 931-937.	1.0	6
17	Management of lipid-lowering therapy in patients with cardiovascular events in the UK: a retrospective cohort study. <i>BMJ Open</i> , 2017, 7, e013851.	0.8	21
18	Second-line therapy in diffuse large B-cell lymphoma (DLBCL): treatment patterns and outcomes in older patients receiving outpatient chemotherapy. <i>Leukemia and Lymphoma</i> , 2017, 58, 1094-1104.	0.6	26

#	ARTICLE	IF	CITATIONS
19	Facility-level CKD-MBD composite score and risk of adverse clinical outcomes among patients on hemodialysis. <i>BMC Nephrology</i> , 2016, 17, 166.	0.8	3
20	Quality adjusted life year gains associated with administration of recombinant tissue-type plasminogen activator for treatment of acute ischemic stroke: 1998–2011. <i>International Journal of Stroke</i> , 2016, 11, 198-205.	2.9	1
21	Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK. <i>BMJ Open</i> , 2016, 6, e011805.	0.8	29
22	Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World Data. <i>Medical Care</i> , 2016, 54, 343-349.	1.1	23
23	Racial and Ethnic Variability in the Prevalence and Incidence of Comorbidities Associated with Gastric Cancer in the United States. <i>Journal of Gastrointestinal Cancer</i> , 2016, 47, 168-181.	0.6	7
24	Hospitalizations in pediatric patients with immune thrombocytopenia in the United States. <i>Platelets</i> , 2016, 27, 472-478.	1.1	14
25	Systematic Literature Review of the Global Incidence and Prevalence of Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 5930-5930.	0.6	14
26	Refining the definition of clinically important mineral and bone disorder in hemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1336-1344.	0.4	15
27	Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States. <i>Value in Health</i> , 2015, 18, 876-883.	0.1	10
28	Estimated Cases of Blindness and Visual Impairment from Neovascular Age-Related Macular Degeneration Avoided in Australia by Ranibizumab Treatment. <i>PLoS ONE</i> , 2014, 9, e101072.	1.1	43
29	Prevalence and incidence of comorbidities in elderly women with ovarian cancer. <i>Gynecologic Oncology</i> , 2013, 129, 346-352.	0.6	25
30	CKD—Mineral and Bone Disorder and Risk of Death and Cardiovascular Hospitalization in Patients on Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 2132-2140.	2.2	94
31	Patterns Of Care, Survival, and Costs Of Second-Line Treatment In Medicare Beneficiaries With Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2013, 122, 2936-2936.	0.6	2
32	A novel approach to the evaluation of bleeding-related episodes in patients with chronic immune thrombocytopenia. <i>Current Medical Research and Opinion</i> , 2012, 28, 789-796.	0.9	9
33	Impact on Medical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients: An Observational Cohort Study Based on SEER-Medicare. <i>Journal of Cancer Epidemiology</i> , 2012, 2012, 1-13.	0.5	20
34	An observational study of the prevalence and incidence of comorbid conditions in older women with breast cancer. <i>Annals of Oncology</i> , 2012, 23, 1756-1765.	0.6	37
35	Inverse Probability Weighted Least Squares Regression in the Analysis of Time-Censored Cost Data: An Evaluation of the Approach Using SEER-Medicare. <i>Value in Health</i> , 2012, 15, 656-663.	0.1	19
36	The burden of immune thrombocytopenia in adults: Evaluation of the thrombopoietin receptor agonist romiplostim. <i>Journal of Medical Economics</i> , 2012, 15, 956-976.	1.0	9

#	ARTICLE	IF	CITATIONS
37	Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. <i>Journal of Medical Economics</i> , 2012, 15, 712-723.	1.0	49
38	Epidemiology and outcomes of previously undiagnosed diabetes in older women with breast cancer: an observational cohort study based on SEER-Medicare. <i>BMC Cancer</i> , 2012, 12, 613.	1.1	19
39	Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma. <i>Cancer</i> , 2012, 118, 6079-6088.	2.0	28
40	Evaluation of bleeding-related episodes in patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care. <i>International Journal of Hematology</i> , 2012, 96, 26-33.	0.7	20
41	Infused Therapy and Survival in Older Patients Diagnosed with Metastatic Breast Cancer who Received Trastuzumab. <i>Cancer Investigation</i> , 2011, 29, 573-584.	0.6	19
42	An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia. <i>Blood</i> , 2011, 117, 3505-3513.	0.6	34
43	Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. <i>Blood</i> , 2011, 118, 4808-4816.	0.6	81
44	The association of vitamin D use with hypercalcemia and hyperphosphatemia in hemodialysis patients: a case-crossover study. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 914-921.	0.9	17
45	Health care utilization and mortality among elderly patients with myelodysplastic syndromes. <i>Annals of Oncology</i> , 2011, 22, 1181-1188.	0.6	19
46	Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL). <i>BMC Cancer</i> , 2010, 10, 625.	1.1	38
47	Estimating recurrences prevented from using trastuzumab in HER2/neu-positive adjuvant breast cancer in the United States. <i>Cancer</i> , 2010, 116, 5575-5583.	2.0	10
48	Survival in elderly follicular lymphoma patients who receive frontline chemo-immunotherapy. <i>American Journal of Hematology</i> , 2010, 85, 963-967.	2.0	6
49	Effect of Epoetin Alfa Dose Changes on Hemoglobin and Mortality in Hemodialysis Patients with Hemoglobin Levels Persistently below 11 g/dL. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 630-637.	2.2	49
50	Cost and mortality associated with hospitalizations in patients with immune thrombocytopenic purpura. <i>American Journal of Hematology</i> , 2009, 84, 631-635.	2.0	42
51	Short-term and long-term failure of laparoscopic splenectomy in adult immune thrombocytopenic purpura patients: A systematic review. <i>American Journal of Hematology</i> , 2009, 84, 743-748.	2.0	84
52	Effect of Adherence on Lifetime Fractures in Osteoporotic Women Treated With Daily and Weekly Bisphosphonates. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 1819-1826.	3.1	22
53	Evaluation of Bleeding-Related Episodes in Patients with Chronic Immune Thrombocytopenic Purpura (ITP) Receiving Romiplostim or Medical Standard of Care.. <i>Blood</i> , 2009, 114, 1311-1311.	0.6	1
54	Evaluation of Bleeding-Related Episodes in Patients with Chronic Immune Thrombocytopenia (ITP) Treated with Romiplostim in Two Phase 3 Placebo-Controlled Clinical Trials.. <i>Blood</i> , 2009, 114, 891-891.	0.6	19

#	ARTICLE	IF	CITATIONS
55	Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer. <i>Clinical Therapeutics</i> , 2008, 30, 775-784.	1.1	22
56	Consistent Control of Mineral and Bone Disorder in Incident Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 1423-1429.	2.2	122
57	Abnormal Bone and Mineral Metabolism in Kidney Transplant Patients – A Review. <i>American Journal of Nephrology</i> , 2008, 28, 246-253.	1.4	71
58	Initial and Long-Term Outcomes of Splenectomy in Adult Immune Thrombocytopenic Purpura (ITP) Patients: A Systematic Review and Meta-Analysis.. <i>Blood</i> , 2007, 110, 1321-1321.	0.6	1
59	Mortality differences among organisms causing septicemia in hemodialysis patients. <i>Hemodialysis International</i> , 2006, 10, 56-62.	0.4	60
60	PTH and the Risks for Hip, Vertebral, and Pelvic Fractures Among Patients on Dialysis. <i>American Journal of Kidney Diseases</i> , 2006, 47, 149-156.	2.1	271
61	Thyroid Status, Cardiovascular Risk, and Mortality in Older Adults. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1033.	3.8	700
62	Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. <i>Kidney International</i> , 2005, 68, 1793-1800.	2.6	499
63	Clinical and Economic Outcomes of Staphylococcus aureus Septicemia in ESRD Patients Receiving Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2005, 46, 301-308.	2.1	65
64	Effect of Thyroxine Therapy on Serum Lipoproteins in Patients with Mild Thyroid Failure: A Quantitative Review of the Literature*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 2993-3001.	1.8	322
65	WHEN TO TREAT MILD HYPOTHYROIDISM. <i>Endocrinology and Metabolism Clinics of North America</i> , 2000, 29, 399-415.	1.2	70
66	More on Screening for Mild Thyroid Failure-Reply. <i>JAMA - Journal of the American Medical Association</i> , 1997, 277, 459.	3.8	0
67	DECISION ANALYSIS IN ENDOCRINOLOGY AND METABOLISM. <i>Endocrinology and Metabolism Clinics of North America</i> , 1997, 26, 89-111.	1.2	9
68	Should Physicians Screen for Mild Thyroid Failure?-Reply. <i>JAMA - Journal of the American Medical Association</i> , 1996, 276, 1550.	3.8	0
69	Screening for Mild Thyroid Failure at the Periodic Health Examination. <i>JAMA - Journal of the American Medical Association</i> , 1996, 276, 285.	3.8	151